Lilly to acquire biopharma company DICE Therapeutics in $2.4bn deal
Eli Lilly and Company (Lilly) has agreed to acquire US-based biopharmaceutical company DICE Therapeutics, listed on the Nasdaq, in an all-cash deal worth $2.4 billion. DICE Therapeutics has developed the DELSCAPE technology platform for developing novel oral therapeutic candidates, including oral IL-17 inhibitors currently in clinical development, to address chronic diseases in immunology. Patrik Jonsson […]